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Polymorphism in the 2-adernergic receptor and lipoprotein lipase
genes as risk determinants for idiopathic venous thromboembolism: A
multilocus, population-based prospective genetic analysis
Zee RY, Cook NR, Cheng S, et al. Circulation 2006;113:2193-200.
Conclusion: There are polymorphisms of the lipoprotein lipase genes
and the 2-adernergic receptor genes that appear to increase the risk of
venous thromboembolism.
Summary: Genes of coagulation, inflammation, and lipid metabolism
pathways are implicated in the risk of idiopathic venous thromboembolism
(VTE). The authors used DNA samples collected at baseline in the Physi-
cians Health Study. They genotyped 92 polymorphisms from 56 candidate
genes in 304 individuals in whom VTE developed (156 secondary and 144
idiopathic cases) and from 2070 individuals who remained free of vascular
disease. There was a mean follow-up of 13.2 years to determine whether
these polymorphisms contributed to the risk of VTE.
With respect to the occurrence idiopathic VTE, the factor V Leiden
mutation confirmed an odds ratio for VTE of 5.13 (95% confidence interval
[CI], 3.24-8.14; P  .0001), the N291S lipoprotein lipase gene polymor-
phism conferred an odds ratio of 3.09 (95% CI, 1.56 to 6.09; P .01), and
the Q27E 2-adernergic receptor gene polymorphism conferred an odds
ratio of 1.40 (95% CI, 1.09 to 1.79; P  .006).
Comment: Blood clots occur for a reason; and idiopathic VTE occurs
for a reason. I suspect that in addition to the major hypercoagulable
abnormalities that had been identified such as factor V Leiden and the
prothrombin gene mutation, there are going to be dozens of genetic
polymorphisms that alone or in combination with relatively mild clinical risk
factors for VTE result in an increased risk for VTE.
Pregnancy-associated plasma protein-A is markedly expressed by
monocyte-macrophage cells in vulnerable and ruptured carotid
atherosclerotic plaques: A link between inflammation and cerebro-
vascular events
Sangiorgi G, Mauriello A, Bonanno E, et al. J Am Coll of Cardiol 2006;47:
2201-11.
Conclusion:Histologic, experimental, and clinical studies have linked
atherosclerosis with inflammation. Unstable carotid plaques produce symp-
toms primarily by disruption and distal embolization. A number of biologic
markers may help identify unstable carotid plaques.
Summary: In this study, the authors investigated the role of pregnancy-
associated protein-A (PAPP-A) as a marker of potential carotid plaque
destabilization and rupture. After endarterectomy, carotid plaques and
serologic PAPP-A levels from 72 patients were analyzed. Indication for
endarterectomy was major stroke in 19 and transient ischemic attack in 24.
Twenty-nine patients were asymptomatic. As determined by histologic
examination, there were three plaque groups: group 1, stable plaques (n 
38); group 2, vulnerable plaques (n  13); and group 3, ruptured plaques
with thrombus (n  14). Plaques were examined for PAPP-A, smooth
muscle cells, T lymphocytes, and macrophages using immunohistochemical
(ICM) staining. Local PAPP-A production was assessed with polymerase
chain reaction (PCR), and double immunofluorescence microscopy was
used to characterize cell types expressing PAPP-A.
Serologic values of PAPP-A were group 1, 4.02 0.18 mIU/L; group
2, 7.43 0.97 mIU/L; and group 3, 6.97 0.75 mIU/L (1 vs 3, P .01;
1 vs 2, P  .004; 2 vs 3, P  .71, respectively). Expression of PAPP-A
showed mean scores of 0.62  0.06 for stable plaques of group 1, 2.54 
0.14 for vulnerable plaques of group 2, and 2.71  0.12 for ruptured
plaques (1 vs 2, P .001; 1 vs 3, P .001; 2 vs 3, P .37, respectively). In
groups 2 and 3, but not in group 1, PCR demonstrated local messenger
RNA PAPP-A production and double ICM confirmed monocyte/macro-
phage expression of PAPP-A.
Comment: It appears that PAPP-A is another potential marker of
carotid plaque destabilization. We are slowly moving towards identifying
which plaques are the most dangerous. What is truly needed, however, is the
identification of the asymptomatic plaques most likely to result in neurologic
symptoms. The next step should be to determine if PAPP-A values can
predict which initially asymptomatic plaques will eventually produce neuro-
logic symptoms.
Effects of statins on renal function after aortic cross clamping during
major vascular surgery
Schouten O, Kox NFM, Boersma E, et al. Am J Cardiol 2006;97:1383-85.
Conclusion: Statins may enhance preservation of renal function after
suprarenal aortic clamping.
Summary: Suprarenal aortic clamping can result in renal dysfunction.
This renal dysfunction is associated with increased postoperative morbidity
and mortality. In this study, the authors sought to evaluate the effects of
statins on renal function in patients undergoing suprarenal aortic cross-
clamping. From 1995 to 2005, the authors identified 77 patients with
normal preoperative renal function who required suprarenal aortic clamping
during a vascular surgical procedure. Of these, 28 patients were statin users.
Their mean age was 69  8 years, and 57 were men and 20 were women.
Creatinine levels were obtained before surgery and at days 1, 2, 3, 7, and 10
after surgery and compared between statin users and nonusers. An analysis of
variance model was used to provide adjustment for clamping time and blood
loss.
Before aortic cross-clamping, no differences were found in baseline
clinical characteristics or preoperative creatinine levels (0.93 vs 0.96mg/dL,
P  .59). There were also no differences in glomerular filtration rates
between the statin users and nonstatin users (79 vs 73 mL/min, P  0.1).
After vascular surgery with aortic cross-clamping above the renal arteries,
postoperative creatinine levels during the 30 days after surgery were
lower in statin users than in nonusers (analysis of variance P  .01, 1.17 vs
1.98 mg/dL). All patients that required postoperative hemodialysis were
nonstatin users (n  7, 9.1%).
Comment: It seems every month a new pleiotropic effect of statins is
discovered. Renal protective effects of statins have been demonstrated in
animal models and are thought to reflect the moderating influence of statins
on endothelial ischemic dysfunction and inflammation. Further work is
required to determine when statins must be initiated before aortic clamping
and what the optimal doses are to minimize ischemia-induced renal dysfunc-
tion.
The risk of hemorrhage among patients with warfarin-associated
coagulopathy
Garcia DA, Regan S, Crowther M, et al. J Am Coll Card 2006;47:804-8.
Conclusion: The 30-day risk of major bleeding is 1% in patients
treated with warfarin who develop an international normalized ratio (INR)
of between 5.0 and 9.0.
Summary: The authors sought to determine the risk of major bleeding
30 days in patients who were on warfarin therapy and who developed an
INR5.0. There were 101 centers that prospectively assembled a cohort of
6761 patients receiving warfarin. In this cohort, 1104 patients had a first
episode of INR 5.0, with 979 being eligible for the study. The primary
outcome variables were major hemorrhage (defined as fatal bleeding, bleed-
ing leading to hospitalization, bleeding requiring a transfusion of at least 2
units of packed red cells), or bleeding in a critical site such as intracranially or
in the retroperitoneum. All other bleeding episodes were considered minor.
Complete follow-up information was available in 976 (99.7%) of the eligible
patients.
Of the eligible patients, 937 (96%) had INR values between 5.0 and
9.0, with 80% of these patients having INR values 7.0. There was a 1.3%
(n  13) incidence of major hemorrhage during the 30-day follow-up
period. Patients whose INRwas between 5.0 and 9.0 had 0.96% incidence of
major bleeding. No fatal bleeding events occurred. Treatment for elevated
INR was withholding of warfarin in most patients, and only 8.7% treated
with vitamin K. Of the patients treated conservatively and retested on day 4
or 5, 50% then had an INR of 2.0.
Comment:Warfarin coagulopathy is common but easily treated in the
large majority of patients by simply withholding warfarin and rechecking the
INR in a few days. Conservative treatment is indicated in patients with
warfarin therapy who present with INRs that are elevated but9.0. Reduc-
tion in the INR to an acceptable level can be expected within a few days with
a minimal incidence of bleeding complications.
N-acetylcysteine and contrast-induced nephropathy in primary
angioplasty
Marenzi G, Assanelli E, Marana I, et al. New Engl J Med 2006;354:2773-82.
Conclusion: Oral and intravenous N-acetylcysteine may prevent
contrast-medium-induced nephropathy in patients treated with primary
coronary angioplasty for acute myocardial infarction.
Summary: The authors investigated N-acetylcysteine for prevention of
contrast-medium-induced nephropathy in patients undergoing coronary
angioplasty for acute myocardial infarction. This group of patients is char-
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acterized by potential hemodynamic instability, potential coexisting renal
failure, and the need for a high volume of contrast medium. There were 354
consecutive patients undergoing primary angioplasty for myocardial infarc-
tion assigned to one of three groups. Group 1 consisted of 116 patients
assigned a standard dose of N-acetylcysteine (a 600-mg intravenous [IV]
bolus before angioplasty and an oral [po] dose of 600 mg twice daily [bid]
for 48 hours after angioplasty). Group 2 was 119 patients assigned to a
double dose of N-acetylcysteine (a 1200-mg IV bolus and 1200 mg po bid
for 48 hours after angioplasty). There were 119 patients assigned to a
placebo group.
Serum creatinine levels increased 25% or more after intervention in 33%
of the control patients (n  39), in 15% of the standard N-acetylcysteine
dosing group (n 17), and in 8% of the high N-acetylcysteine dosing group
(n  10; P  .001). Patients in whom contrast-medium-induced nephrop-
athy developed had higher in-hospital mortality (26% vs 1%, P  .001).
Rates of a composite end point of death, acute renal failure requiring
temporary renal replacement therapy, or need for mechanical ventilation
were 18% in the placebo group, 7% in the standard N-acetylcysteine group,
and 5% in the high dose N-acetylcysteine group (P  .002).
Comment: This is obviously a study of urgent angiography and angio-
plasty in patients with coronary artery disease. However, it is likely the results
of this study can be extrapolated to patients with peripheral vascular disease.
The importance of the report resides in the fact it may be possible to prevent
contrast nephropathy with N-acetylcysteine prophylaxis administered at the
time of the angiographic procedure rather than beginning in the days before
the procedure.
Effects of argatroban therapy, demographic variables, and platelet
count on thrombotic risk in heparin-induced thrombocytopenia
Lewis BE, Wallis DE, Hursting MJ, et al. Chest 2006;129:1407-16.
Conclusion: Argatroban provides excellent antithrombotic therapy in
patients with heparin-induced thrombocytopenia (HIT).
Summary: The authors evaluated thrombotic risk of HIT with respect
to the effects of argatroban, a direct thrombin inhibitor, patient demograph-
ics, and platelet count. This was a retrospective study designed to analyze
thrombotic outcomes in 882 patients with HIT, of whom 697 patients who
received argatroban at doses of 1.7 to 2.0 g/(kg · min) for 5 to 7 days.
These patients were compared with 185 historical control subjects from a
previously reported prospective study. The primary end point was a com-
posite time-to-event analysis that included death owing to thrombosis, a
new thrombosis 37 days, and amputation secondary to HIT-associated
thrombosis. Individual components of the primary end point were also
analyzed, and hazard ratios were estimated for treatment with and without
adjustments for baseline platelet count, race, weight, gender, and age.
Compared with control subjects, argatroban significantly reduced the
thrombotic composite end point (HIT: hazard ratio, 0.33; 95% confidence
interval, 0.20 to 0.54; P .001). For HIT with thrombosis, the hazard ratio
for treatment with argatroban was 0.39 (95% confidence interval, 0.25 to
0.62; P  .001). There was no influence of covariant adjustments. More
patients taking argatroban remained free of thrombotic events during
follow-up than did control subjects. This was independent of whether
baseline thrombosis was present or absent. Argatroban also significantly
reduced new thrombosis (P  .001) and death due to thrombosis (P 
.001). The control group and the argatroban-treated group had similar
major bleeding episodes (6% to 7%, P  .74). Nonwhite patients had a two
times greater risk of thrombotic events. Thrombotic risks were also increased
1.7 times in women vs men with HIT and thrombosis. Thrombotic events
were also increased with decreasing weight or decreasing platelet count.
Comment: This study confirms the effectiveness of argatroban in
treating HIT. Note that HIT patients with lower body weight and more
severe thrombocytopenia, as well as those who were nonwhite, had greater
HIT-associated thrombotic complications.
N-acetylcysteine for the prevention of kidney injury in abdominal
aortic surgery: A randomized, double-blind, placebo-controlled trial
Hynninen MS, Niemi TT, Poyhia R, et al. Anesth Analg 2006;102:1638-45.
Conclusion: N-acetylcysteine does not protect against renal injury
during elective aortic operation.
Summary: There are conflicting results about whether N-acetylcysteine
protects against contrast-induced nephropathy (N Engl J Med 2000; 43:
180-4 and Am J Kidney Disease 2004;43:1-9). In this study, the authors
sought to evaluate whether intravenous N-acetylcysteine can prevent renal
injury in patients undergoing abdominal aortic surgery. This was a prospec-
tive, randomized, placebo-controlled, double-blind trial. Patients without
known renal dysfunction were randomly allocated to receive either
N-acetylcysteine (150 mg/kg) during a 20-minute period, followed by an
infusion of 150 mg/kg in 250 mL of 5% dextrose during 24 hours, or
placebo. The drug infusion was started after induction of anesthesia. Renal
injury was the primary outcome measure as measured by increases in the
urinary N-acetyl--D-glucosaminidase (NAG)/creatinine ratio (indicator of
renal tubular injury) and the urinary albumin/creatinine ratio as an indicator
of glomerular injury. Serum cystatin C concentrations and plasma creatinine
were used to measure renal function.
Seventy patients were randomized: 34 receivedN-acetylcysteine and 35
received the placebo. One was withdrawn from the study when intra-
abdominal carcinomatosis precluded aortic reconstruction. There were 49
patients treated for aneurysm disease and 21 for occlusive disease. Only two
suprarenal aortic clamps were used, both in the placebo group. Aortic
cross-clamp times were a mean of 67 minutes (range, 22 to 159 minutes) in
the N-acetylcysteine group and 74 minutes (range, 22 to 156 minutes) in
the placebo group (P  .350). The differences in the two groups between
length of operation, intraoperative blood loss, and administration of intra-
venous fluids were not significant.
The urinary NAG/creatinine ratio increased from baseline to before
cross-clamp and remained increased on day 5 in both groups. The urinary
albumin/creatinine ratio also increased significantly from baseline to 6 hours
after declamping in the N-acetylcysteine group. There were no significant
changes in the NAG/creatinine ratio and the albumin/creatinine ratio
between the 2 groups. There were no changes in plasma creatinine and
serum cystatin C values between the 2 groups.
Comment: It is known that infrarenal and suprarenal aortic cross-
clamping can induce renal dysfunction. However, it would seem more likely
that suprarenal aortic clamping may produce changes in renal function of
greater magnitude than infrarenal aortic clamping. It would be interesting to
repeat this study in centers with a high volume of thoracoabdominal aneu-
rysm repair, and/or in centers in which there are relatively large numbers of
open abdominal aortic aneurysm repairs requiring suprarenal aortic clamps.
Cerebral emboli as a potential cause of Alzheimer’s disease and vascular
dementia: Case-control study
Purandare N, Burns A, Daly KJ, et al. BMJ 2006;332:1119-22.
Conclusion: Alzheimer’s disease and vascular dementia are associated
with spontaneous cerebral emboli.
Summary: Using a cross-sectional case–control study design, the
authors sought to compare the occurrence of spontaneous cerebral emboli
and venous-to-arterial circulation shunts in control patients without demen-
tia and in patients with vascular dementia or Alzheimer’s disease. There were
150 age-matched and sex-matched controls for the 170 patients with
dementia (85 with Alzheimer’s disease and 85 with vascular dementia).
Patients were excluded from the study if they were taking anticoagulant
therapy or had severe cognitive dysfunction or severe dementia. Spontane-
ous cerebral emboli were detected with transcranial Doppler monitoring of
the middle cerebral artery for 1 hour. Venous-to-arterial circulation shunts
were evaluated using transcranial Doppler in combination with intravenous
microbubbles as an ultrasound contrast agent.
Spontaneous cerebral emboli were detected in 40% of the patients with
Alzheimer’s disease (n  32) and in 37% of patients with vascular dementia
(n  31). In contrast, spontaneous cerebral emboli were detected in only
14% of control patients. Odds ratios adjusted for vascular risk factors for
spontaneous cerebral emboli were 2.70 (95% confidence interval, 1.18 to
6.21) for Alzheimer’s disease and 5.36 (95% confidence interval, 1.24 to
23.18) for vascular dementia. Carotid disease was no more frequent in the
dementia patients than the control patients. A venous-to-arterial shunt
indicative of a patent foramen ovale was found in 32% of Alzheimer’s disease
patients, in 29% of vascular dementia patients, and in about 21% of control
patients, giving nonsignificant odds ratios for arterial circulation shunts as a
contribution to Alzheimer’s disease or vascular dementia.
Comment: Spontaneous cerebral emboli can be detected in more than
half of patients with 70% carotid artery stenosis. This study suggests that
spontaneous cerebral emboli come from other sources in addition to carotid
artery disease and that these sources of cerebral emboli may contribute to the
development of Alzheimer’s disease or vascular dementia. It will be interest-
ing to see if long-term pharmacologic manipulation can someday reduce
spontaneous cerebral emboli in patients with Alzheimer’s disease or vascular
dementia as well as in patients with carotid stenosis.
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